Stocktoria
SpyGlass Pharma, Inc. SGP
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2026-02-06
Chart by TradingView
3/9
Piotroski F — financial health
-9.89
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$41.4M | -$27.1M |
| Net income | -$39.9M | -$29.2M |
| Operating cash flow | -$32.7M | -$22.0M |
| Free cash flow | -$33.5M | -$24.0M |
| Total assets | $115.9M | $23.3M |
| Total liabilities | $10.2M | $11.2M |
| Shareholders' equity | -$98.8M | -$60.5M |
| Ratios | ||
| Return on assets | -34.4% | -125.1% |
| Return on equity | 40.3% | 48.2% |
| Current ratio | 12.67 | 2.23 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.89 (distress)
- Working capital / assets 0.865
- Retained earnings / assets -0.904
- EBIT / assets -0.358
- Equity / liabilities -9.722
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001778922 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.